Bridge Therapeutics is developing critically needed treatments for opioid use disorder and severe chronic pain. Opioid Use Disorder is a $6B market affecting 6 Million people. Chronic pain is a $20B market affecting 50 Million people.
BT-219 or Bunalz™ is an investigational new drug applying Catalent’s Zydis® ODT (orally disintegrating tablet) delivery technology of buprenorphine and naloxone, which are the active ingredients in Suboxone®. Catalent’s proprietary Zydis® technology is a unique, freeze-dried, sublingual tablet with advantages over other forms of administration.
BT-205 or Bucam™ is a patented combination of a partial opioid agonist (Buprenorphine) and an NSAID pain reliever (Meloxicam) for treatment of moderate to severe chronic pain.
Bridge seeks approval of its drug candidates through the United States Food and Drug Administration (FDA) and through the European Medicines Agency (EMA).
Please fill out the form below to contact us and learn more about how these products can provide better care for those with Opioid Use Disorder or moderate to severe chronic pain.